Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue with 94% structural homology to native human GLP-1. Its C18 fatty diacid chain enables reversible albumin binding, conferring a half-life of approximately 7 days in vivo. It has become one of the most researched metabolic peptides globally, featuring in numerous peer-reviewed studies on insulin secretion, appetite regulation, hepatic lipogenesis, and cardiovascular risk reduction. Research-grade semaglutide is produced via solid-phase peptide synthesis and purified to ≥99.4% purity as confirmed by reversed-phase HPLC and ESI-MS.
| Molecular Formula | C₁₈₄H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 g/mol |
| Sequence | 34 amino acid GLP-1 analogue with C18 fatty acid chain |
| Purity | ≥99.4% (HPLC) |
| Format | Lyophilized powder |
| Appearance | White powder |
| Solubility | Sterile water (pH 7.4) |
| Storage | −20°C long-term |
| Batch No | CB-2024-SEMA-03 |
| Testing | HPLC + ESI-MS + Endotoxin |
| Origin | Solid-phase synthesis |

Reviews
There are no reviews yet.